Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II

Manylion Llyfryddiaeth
Prif Awduron:	Ana Sandoval-Rodriguez, Aldo Torre-Delgadillo, Juan Armendariz-Borunda
Fformat:	Erthygl
Iaith:	English
Cyhoeddwyd:	Frontiers Media S.A. 2024-02-01
Cyfres:	Frontiers in Medicine
Pynciau:	liver fibrosis MAFLD MASLD steatotic liver disease non-alcoholic steatohepatitis (NASH)
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fmed.2024.1371720/full

Eitemau Tebyg

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
gan: Yvonne Burmeister, et al.
Cyhoeddwyd: (2023-12-01)

Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences
gan: Apichat Kaewdech, et al.
Cyhoeddwyd: (2024-04-01)

Adding to the confusion in more than just the name
gan: Jacob George
Cyhoeddwyd: (2023-10-01)

Editorial: The NAFLD-MAFLD conundrum
gan: Andrea Dalbeni, et al.
Cyhoeddwyd: (2023-09-01)

From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
gan: Alexandra Gatzios, et al.
Cyhoeddwyd: (2022-01-01)

Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study
gan: Xue Bao, et al.
Cyhoeddwyd: (2024-06-01)

MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease
gan: Ziyan Pan, et al.
Cyhoeddwyd: (2024-09-01)

Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis
gan: Jiaxin Chen, et al.
Cyhoeddwyd: (2024-06-01)

Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD)
gan: Olga Estévez-Vázquez, et al.
Cyhoeddwyd: (2021-09-01)

Editorial: Multi-organ linkage pathophysiology and therapy for NAFLD and NASH
gan: Takefumi Kimura, et al.
Cyhoeddwyd: (2024-06-01)

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
gan: Gary Huang, et al.
Cyhoeddwyd: (2023-10-01)

Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
gan: Wesam Bahitham, et al.
Cyhoeddwyd: (2024-02-01)

The association between diverse serum folate with MAFLD and liver fibrosis based on NHANES 2017–2020
gan: Jiacheng Cai, et al.
Cyhoeddwyd: (2024-03-01)

NAFLD: Mechanisms, Treatments, and Biomarkers
gan: Fatiha Nassir
Cyhoeddwyd: (2022-06-01)

Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice
gan: Julia R.C. Nunes, et al.
Cyhoeddwyd: (2024-06-01)

Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis
gan: Natchaya Polpichai, et al.
Cyhoeddwyd: (2024-12-01)

Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice
gan: Carlos Cuño-Gómiz, et al.
Cyhoeddwyd: (2023-11-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
gan: Valeria Michelle Fernández-Garibay, et al.
Cyhoeddwyd: (2025-01-01)

Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population
gan: Haoxuan Zou, et al.
Cyhoeddwyd: (2024-07-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
gan: D. V. Garbuzenko
Cyhoeddwyd: (2022-01-01)

Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis
gan: Bruno Ramos-Molina, et al.
Cyhoeddwyd: (2024-06-01)

Diet, oxidative stress and MAFLD: a mini review
gan: Zenan Hu, et al.
Cyhoeddwyd: (2025-03-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
gan: Katharina Staufer, et al.
Cyhoeddwyd: (2023-07-01)

Diagnostic performance of FibroTouch® in assessing hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: An Asian experience
gan: Thanikan Sukaram, et al.
Cyhoeddwyd: (2025-01-01)

Adaptation of Clinical Practice Guideline for Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in Isfahan Province
gan: Sayed Mohammad Hosseeini, et al.
Cyhoeddwyd: (2024-08-01)

Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver diseaseKey points
gan: Guillaume Henin, et al.
Cyhoeddwyd: (2024-02-01)

The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis—Systematic Review and Meta-Analysis
gan: Abdulrahman Ismaiel, et al.
Cyhoeddwyd: (2021-12-01)

Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease
gan: Yuri Cho
Cyhoeddwyd: (2024-11-01)

A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study
gan: Jeffrey V. Lazarus, et al.
Cyhoeddwyd: (2025-01-01)

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
gan: Andrea Boccatonda, et al.
Cyhoeddwyd: (2023-03-01)

Associations of life’s essential 8 with MAFLD and liver fibrosis among US adults: a nationwide cross-section study
gan: Depeng Liang, et al.
Cyhoeddwyd: (2024-06-01)

Nonalcoholic Fatty Liver Disease—A Concise Review of Noninvasive Tests and Biomarkers
gan: Tamara Bassal, et al.
Cyhoeddwyd: (2022-11-01)

Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study
gan: Ilkay Ergenc, et al.
Cyhoeddwyd: (2024-08-01)

Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score
gan: Pimsiri Sripongpun, et al.
Cyhoeddwyd: (2024-10-01)

Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease
gan: Ahmed Ebeid, et al.
Cyhoeddwyd: (2025-02-01)

Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
gan: David Pérez Compte, et al.
Cyhoeddwyd: (2024-04-01)

Editorial: Unraveling the links between nutrients and metabolic dysfunction-associated liver disease: insights and implications
gan: Bruno Ramos-Molina, et al.
Cyhoeddwyd: (2024-11-01)

Corrigendum: Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis
gan: Christian Stoess, et al.
Cyhoeddwyd: (2024-10-01)

Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis
gan: Christian Stoess, et al.
Cyhoeddwyd: (2023-08-01)

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
gan: Reddemma Sandireddy, et al.
Cyhoeddwyd: (2024-07-01)